BSFA.STU ANI Pharmaceuticals Inc
- Market cap
- EUR 1.48B
- P/E
- 16.3x
- P/B
- 2.77x
- ROE
- 18.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BSFA.STU undervalued?
Graham numberBSFA.STU trades 41.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANI Pharmaceuticals Inc fundamental analysis
No fundamental analysis for ANI Pharmaceuticals Inc yet.
ANI Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and m…
Full company profileANI Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ANI Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 129M | 177M | 202M | 207M | 208M | 216M | 316M | 487M | 614M | 883M | 1.01B |
| Gross Profit | 79.8M | 97.8M | 129M | 143M | 121M | 116M | 178M | 305M | 364M | 542M | 620M |
| Operating Income | 26.8M | 29.2M | 35.4M | 16.4M | -15.6M | -26.6M | -25.7M | 49.5M | 2.22M | 81.2M | 157M |
| EBITDA | - | 56.3M | 68.6M | 60.7M | 28.1M | 3.12M | 22.4M | 107M | 63.1M | 207M | 251M |
| Net Income | 3.93M | -1.08M | 15.5M | 6.09M | -22.5M | -42.6M | -47.9M | 18.8M | -18.5M | 78.3M | 108M |
| EPS | - | -0.09 | 1.31 | 0.50 | -1.82 | -2.53 | -2.74 | 0.92 | -0.88 | 3.48 | 4.72 |
| Balance Sheet | |||||||||||
| Total Assets | 323M | 412M | 431M | 457M | 461M | 772M | 760M | 904M | 1.28B | 1.44B | 1.49B |
| Total Liabilities | 153M | 237M | 233M | 244M | 265M | 413M | 422M | 447M | 855M | 900M | 897M |
| Shareholders' Equity | 170M | 175M | 197M | 213M | 196M | 359M | 339M | 458M | 429M | 541M | 597M |
| Cash & Short-term Investments | 27.4M | 31.1M | 43.0M | 62.3M | 7.86M | 100M | 48.2M | 221M | 145M | 286M | 360M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 27.5M | 39.4M | 67.1M | 45.6M | 15.3M | 3.32M | -31.2M | 119M | 64.0M | 185M | 230M |
| Capital Expenditure | 149M | 10.4M | 5.74M | 6.64M | 6.14M | 2.56M | 8.88M | 18.5M | 17.0M | 34.3M | 28.8M |
| Free Cash Flow | - | -68.6M | 56.2M | 18.1M | -53.1M | -20.3M | -47.7M | 100M | 47.1M | 151M | 201M |
| Ratios | |||||||||||
| ROE | 2.3% | -0.6% | 7.9% | 2.9% | -11.5% | -11.9% | -14.1% | 4.1% | -4.3% | 14.5% | 18.2% |
| ROA | 1.2% | -0.3% | 3.6% | 1.3% | -4.9% | -5.5% | -6.3% | 2.1% | -1.4% | 5.4% | 7.3% |
| Net Profit Margin | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% | 10.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ANI Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 1.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.16M | 0.05 | 1.5% |
| 2024 | USD 1.63M | 0.08 | - |
| 2023 | USD 1.63M | 0.08 | 8.7% |
| 2022 | USD 1.63M | 0.09 | - |
| 2021 | USD 190K | 0.01 | - |
| 2020 | USD 190K | 0.02 | - |
| 2019 | EUR 190K | 0.02 | 3.1% |
| 2018 | EUR 190K | 0.02 | 1.2% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ANI Pharmaceuticals Inc
- Insiders 5.39%
- Institutions 94.61%
- Public & others 0.00%
- Shares outstanding 23.0M
- Free float 19.7M
ANI Pharmaceuticals Inc company profile
- Company name
- ANI Pharmaceuticals Inc
- Ticker
- BSFA.STU
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 642
- Fiscal year end
- December
- Address
- 210 Main Street West, Baudette, MN, United States, 56623
- Phone
- 218 634 3500
- Website
- anipharmaceuticals.com
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals Inc management
10- Mr. Nikhil LalwaniPresident, CEO & Director · born 1978
- Mr. Stephen P. CareySenior VP of Finance & CFO · born 1971
- Ms. Meredith W. Cook J.D.Senior VP, General Counsel & Corporate Secretary · born 1974
- Mr. Christopher K. MutzSenior VP & Head of Rare Disease · born 1972
- Mr. Ori GutwergSenior Vice President of Generics · born 1975
- Mr. Muthusamy Shanmugam MS R.Ph.Head of R&D and COO of New Jersey Operations · born 1968
- Ms. Irina Rivkind KofflerVice President of Investor Relations
- Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare Disease
- Mr. Chad GassertSenior Vice President of Corporate Development & Strategy · born 1976
- Ms. Krista L. DavisSenior VP & Chief Human Resources Officer · born 1973